AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12651679 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.10% plus 0.5 microg/mL of sufentanil
Number of subjects: 130
Study 10765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (n = 106); mothers chewed xylitol‐sweetened gum (65% w/w) at least 2 or 3 times a day, starting three months after delivery.
Number of subjects: 169
Study 10765964 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (n = 30); varnish treatments at 6, 12, and 18 months after delivery.
Number of subjects: 169
Study 10765964 — intervention group
Group type: COMPARATOR
Intervention: Fluoride (n = 33); varnish treatments at 6, 12, and 18 months after delivery.
Number of subjects: 169
Study 8807372 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary nursing in experimental units (after t1)
Number of subjects: 0
Study 8807372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no changes until t2)
Number of subjects: 0
Study 1578942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with additional allogeneic bone marrow transplantation
Number of subjects: 156
Study 1578942 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplant using unpurged marrow
Number of subjects: 156
Study 1578942 — intervention group
Group type: COMPARATOR
Intervention: Stopping therapy
Number of subjects: 156
Study 3948357 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 180 or 240 mg daily
Number of subjects: 3837
Study 3948357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31892636 — intervention group
Group type: EXPERIMENTAL
Intervention: IV thrombolysis (alteplase 0.9 mg/kg)
Number of subjects: 859
Study 29843670 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Change intervention (four-session group obesity prevention education)
Number of subjects: 360
Study 29843670 — intervention group
Group type: COMPARATOR
Intervention: Control group (four-session personal and food hygiene education)
Number of subjects: 360
Study 27881914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa intake once daily (17 g, except Sundays) for 12 weeks
Number of subjects: 26
Study 27881914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa intake twice daily every other day (17 g) for 12 weeks
Number of subjects: 26
Study 23425082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose for 3 months
Number of subjects: 60
Study 23425082 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 21496065 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg co-administered with fesoterodine 8 mg
Number of subjects: 14
Study 21496065 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg alone
Number of subjects: 14
Study 19059539 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK
Number of subjects: 34
Study 19059539 — intervention group
Group type: EXPERIMENTAL
Intervention: RAISIN
Number of subjects: 34
Study 19059539 — intervention group
Group type: EXPERIMENTAL
Intervention: RAISIN + WALK
Number of subjects: 34
Study 19059539 — intervention group
Group type: EXPERIMENTAL
Intervention: RAISIN, WALK, RAISIN + WALK
Number of subjects: 34
Study 17196454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (extended-release formulation in MARISA, CARISA, ERICA; immediate release in RAN080)
Number of subjects: 1737
Study 17196454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 1737
Study 15071489 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine monotherapy
Number of subjects: 10
Study 15071489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11181777 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 226
Study 11181777 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin plus cyclophosphamide plus 4'-epidoxorubicin (PCDE)
Number of subjects: 226
Study 9751354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study 9751354 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 1229
Study 9751354 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 1229
Study 9751354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 1229
Study 8313800 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and levamisole
Number of subjects: 0
Study 8313800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment with radiotherapy and chemotherapy
Number of subjects: 0
Study 3354256 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 7, and 21 (Group IA)
Number of subjects: 82
Study 3354256 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 28, and 56 (Group IB)
Number of subjects: 82
Study 3354256 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 3, 7, 14, 28, and 90 (Group II)
Number of subjects: 82
Study 3354256 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified inactivated rabies vaccine (PVRV), 0.5 ml, single booster for previously immunized individuals (Group III)
Number of subjects: 82
Study 31221722 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) treatment
Number of subjects: 48
Study 31221722 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 31221722 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label phase with BoNT treatment
Number of subjects: 48
Study 28600025 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVE© platform for chronic disease self-management
Number of subjects: 0
Study 24036971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser application after SRP (Group 3)
Number of subjects: 39
Study 24036971 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser application (Group 1)
Number of subjects: 39
Study 24036971 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (Group 2)
Number of subjects: 39
Study 23219541 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 50
Study 21774743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 16
Study 21774743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18560537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (0.5 mg)
Number of subjects: 17
Study 18560537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (2 mg)
Number of subjects: 17
Study 18560537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (0.5 mg and 2 mg)
Number of subjects: 17
Study 18560537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22333546 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT plus TACE
Number of subjects: 145
Study 22333546 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 145
Study 15953905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 500/125 mg 3 times a day for 4 days
Number of subjects: 490
Study 15953905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 12006119 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 165
Study 12006119 — intervention group
Group type: COMPARATOR
Intervention: Needle insertion control
Number of subjects: 165
Study 12006119 — intervention group
Group type: COMPARATOR
Intervention: No-needle relaxation control
Number of subjects: 165
Study 9801110 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.05% PGE1 in liposomal formulations
Number of subjects: 5
Study 9801110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8746051 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 10
Study 8746051 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic banding ligation
Number of subjects: 10
Study 2784684 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 2784684 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 683118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe++ sulfate in a weak gelatine capsule (A)
Number of subjects: 12
Study 683118 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (commercial preparation)
Number of subjects: 12
Study 683118 — intervention group
Group type: COMPARATOR
Intervention: Preparation C (commercial preparation)
Number of subjects: 12
Study 30380357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-multivitamin combination product (treatment group, n=20)
Number of subjects: 41
Study 30380357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group, n=21)
Number of subjects: 41
Study 29044466 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage therapy (SMT)
Number of subjects: 66
Study 29044466 — intervention group
Group type: COMPARATOR
Intervention: light touch (LT)
Number of subjects: 66
Study 29044466 — intervention group
Group type: COMPARATOR
Intervention: waitlist control (WLC)
Number of subjects: 66
Study 27097823 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublebase™ gel (2 fingertip units, twice daily for 4 weeks)
Number of subjects: 37
Study 27097823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprobase® cream (2 fingertip units, twice daily for 4 weeks)
Number of subjects: 37
Study 23820561 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR; 70% of the power output at lactate threshold)
Number of subjects: 10
Study 23820561 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study 23820561 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 10
Study 22545980 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 257
Study 22545980 — intervention group
Group type: EXPERIMENTAL
Intervention: Family conflict
Number of subjects: 257
Study 22545980 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-care
Number of subjects: 257
Study 22545980 — intervention group
Group type: EXPERIMENTAL
Intervention: A1c levels
Number of subjects: 257
Study 20805984 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g dried broccoli sprouts for 4 weeks
Number of subjects: 40
Study 20805984 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet (Control)
Number of subjects: 40
Study 18328050 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel crown (SSC)
Number of subjects: 87
Study 18328050 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified open-sandwich restoration
Number of subjects: 87
Study 16700378 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 90
Study 16700378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no external cephalic version attempted)
Number of subjects: 90
Study 12534405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole
Number of subjects: 160
Study 12534405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 12212215 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin 400 mg.d-1 for 10 days
Number of subjects: 78
Study 12212215 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (inotropic agents, diuretic, vasodilator)
Number of subjects: 78
Study 8568124 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 30
Study 8568124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1868860 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (10 units of standard insulin)
Number of subjects: 20
Study 1868860 — intervention group
Group type: COMPARATOR
Intervention: Insulin-placebo treatment
Number of subjects: 20
Study 6751183 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 95
Study 6751183 — intervention group
Group type: COMPARATOR
Intervention: Control (no granulocyte transfusions)
Number of subjects: 95
Study 6751183 — intervention group
Group type: COMPARATOR
Intervention: Control (with recovery of marrow function)
Number of subjects: 95
Study 6751183 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (with recovery of marrow function)
Number of subjects: 95
Study 6751183 — intervention group
Group type: COMPARATOR
Intervention: Control (without recovery of marrow function)
Number of subjects: 95
Study 6751183 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (without recovery of marrow function)
Number of subjects: 95
Study 30909924 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LLINs) distributed to residents along the Padauiri River.
Number of subjects: 208
Study 30909924 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bacabal-rio Aracá and São Sebastião district).
Number of subjects: 208
Study 29559261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic artery grafting with conversion to other conduit strategies
Number of subjects: 1525
Study 29559261 — intervention group
Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery grafting without conversion
Number of subjects: 1525
Study 29559261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic artery grafting with conversion
Number of subjects: 1525
Study 27825901 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic training (KinVis) with motor imagery (MI) during dart throwing, 15 training sessions.
Number of subjects: 53
Study 27825901 — intervention group
Group type: COMPARATOR
Intervention: Control group without motor imagery (MI) during dart throwing, 15 training sessions.
Number of subjects: 53
Study 24924851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) as add-on to cognitive-behavioral therapy (CBT)
Number of subjects: 74
Study 24924851 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 74
Study 22525912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis antigens HSP60, CT376, CT557, and CT443
Number of subjects: 73
Study 22525912 — intervention group
Group type: EXPERIMENTAL
Intervention: CT875 and CT147
Number of subjects: 73
Study 20487351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber (DC) ICDs with SafeR pacing at 60 bpm
Number of subjects: 450
Study 20487351 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber (SC) ICDs with backup pacing at VVI 40 bpm
Number of subjects: 450
Study 18926460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based laparoscopic suturing curriculum (TR group)
Number of subjects: 22
Study 18926460 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical training (NR group)
Number of subjects: 22
Study 15886753 — intervention group
Group type: COMPARATOR
Intervention: SST-A octreotide alone (Group A)
Number of subjects: 22
Study 15886753 — intervention group
Group type: EXPERIMENTAL
Intervention: SST-A octreotide with adjuvant treatment (Group B)
Number of subjects: 22
Study 12585097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordyceps powder 2‐4 g/d before meal and artemisinin 0.6 g/d after meal for 3 years
Number of subjects: 61
Study 12585097 — intervention group
Group type: COMPARATOR
Intervention: Tripterygiitotorum and/or Baoshenkang tablet
Number of subjects: 61
Study 12534118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1 during RSI (Group A)
Number of subjects: 36
Study 12534118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1 after intubation (Group B)
Number of subjects: 36
Study 12534118 — intervention group
Group type: COMPARATOR
Intervention: No fentanyl (Control Group C)
Number of subjects: 36
Study 12534118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl groups (A and B)
Number of subjects: 36
Study 12534118 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 9583842 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐group vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin)
Number of subjects: 132
Study 9583842 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins alone (150 mg ascorbic acid, 67 mg RRR‐alpha‐tocopherol, and 9 mg beta‐carotene)
Number of subjects: 132
Study 9583842 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐group vitamins with antioxidant vitamins
Number of subjects: 132
Study 9583842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 8562173 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 200 mg/m2 i.v. plus 5‐FU 400 mg/m2 i.v. on days 1‐5 every 3 weeks
Number of subjects: 185
Study 8562173 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU 400 mg/m2 i.v. on days 1‐5 every 4 weeks
Number of subjects: 185
Study 2766421 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine and Western Medicine (TCM-WM)
Number of subjects: 59
Study 2766421 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (Control)
Number of subjects: 59
Study 656890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefuroxime intramuscularly and 1 g probenecid orally
Number of subjects: 110
Study 656890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime intramuscularly with 1 g probenecid orally
Number of subjects: 110
Study 31400480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Hormone Therapy (HT)
Number of subjects: 41
Study 31400480 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 41
Study 31400480 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control Group
Number of subjects: 41
Study 25733749 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-implemented communication intervention
Number of subjects: 97
Study 25733749 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 97
Study 23239304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025-inch guide wire and sphincterotome group (n = 50)
Number of subjects: 100
Study 23239304 — intervention group
Group type: COMPARATOR
Intervention: 0.035-inch guide wire and sphincterotome group (n = 50)
Number of subjects: 100
Study 21348577 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor-imagery therapy
Number of subjects: 15
Study 21348577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary therapy)
Number of subjects: 15
Study 19850682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 19850682 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP 150 microg/d
Number of subjects: 279
Study 19850682 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP 300 microg/d
Number of subjects: 279
Study 16452585 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16
Study 16452585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14998677 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal focused ultrasound surgery (FUS)
Number of subjects: 1038
Study 11344699 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 40
Study 11344699 — intervention group
Group type: EXPERIMENTAL
Intervention: cisaprid + famotidine
Number of subjects: 40
Study 11344699 — intervention group
Group type: EXPERIMENTAL
Intervention: cisaprid
Number of subjects: 40
Study 11344699 — intervention group
Group type: EXPERIMENTAL
Intervention: eradication of H.p.
Number of subjects: 40
Study 9833000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 0
Study 9833000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 0
Study 9833000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 0
Study 9833000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study 7862833 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink containing 50 g glucose
Number of subjects: 0
Study 7862833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7862833 — intervention group
Group type: EXPERIMENTAL
Intervention: Series of glucose-containing drinks raised blood glucose levels for 2 hours
Number of subjects: 0
Study 3497777 — intervention group
Group type: EXPERIMENTAL
Intervention: 220C Copper T IUD inserted before leaving the delivery room
Number of subjects: 66
Study 3497777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IUD insertion)
Number of subjects: 66
Study 30529883 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/d of high-cocoa chocolate for 4 weeks
Number of subjects: 32
Study 30529883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alteration in diet or physical activity)
Number of subjects: 32
Study 29908991 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B, administered via intramuscular injections, up to 13 doses over 27 months)
Number of subjects: 1345
Study 29908991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered via intramuscular injections, up to 13 doses over 27 months)
Number of subjects: 1345
Study 29908991 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (in GS-positive population)
Number of subjects: 1345
Study 29908991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in GS-positive population)
Number of subjects: 1345
Study 27217410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent participants (n=16,878)
Number of subjects: 19790
Study 27217410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent participants (n=2912)
Number of subjects: 19790
Study 25397819 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in brief 4-week Mindfulness Based Stress Reduction program (n=19)
Number of subjects: 40
Study 25397819 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, n=21)
Number of subjects: 40